Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment

#3106

Introduction: Selection of third-line treatment after somatostatin analogues (SSA) and Peptide Receptor Radionuclide Therapy (PRRT) for WD-SiNETs remains challenging.

Aim(s): Understand current practice and rationale for decision-making in the 3rd-line setting after SSA and PRRT.

Materials and methods: An online survey (replies collected between 5/8/2020 and 21/9/2020) was built. Weighted average (WA) of likelihood of usage between responders (1 very unlikely; 4 very likely) was used to reflect the relevance of factors explored.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lamarca A

Authors: Lamarca A, Cives M, de Mestier L, Crona J, Spada F,

Keywords: small bowel, well-differentiated, third-line, everolimus, IFN, chemotherapy, liver embolisation, multidisciplinary, survey, decision making,